OCA
CNTX icon

Octagon Capital Advisors’s Context Therapeutics CNTX Stock Holding History

Octagon Capital Advisors’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.69M Sell
3,050,000
-2,200,000
-42% -$4.46M 0.15% 26
2026
Q1 		$13.8M Buy
+5,250,000
New +$12.3M 1.52% 20

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Octagon Capital Advisors's CNTX Position: Q2 2026 in Review

Octagon Capital Advisors reduced its Context Therapeutics (CNTX) stake by 42% in Q2 2026, selling an estimated $4.46M and leaving 3,050,000 shares worth $1.69M. The position accounts for 0.15% of the portfolio, ranked #26.

Octagon Capital Advisors first reported a position in CNTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $13.8M in Q1 2026. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • Octagon Capital Advisors held 3,050,000 shares of Context Therapeutics worth $1.69M as of Q2 2026.
  • Octagon Capital Advisors sold 2,200,000 Context Therapeutics shares in Q2 2026, an estimated $4.46M.
  • Context Therapeutics made up 0.15% of Octagon Capital Advisors's portfolio in Q2 2026, its #26 holding.
  • Octagon Capital Advisors first reported a position in Context Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Octagon Capital Advisors's Context Therapeutics position peaked at $13.8M in Q1 2026.
  • 79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Octagon Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.